PRNewsWire
06 Feb 2026, 02:26 UTC · 32w ago
Verdict
Headline takes no side. We score 9926.HK +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Akeso's drug ivonescimab received Breakthrough Therapy Designation (BTD) from China's NMPA for first-line treatment of advanced biliary tract cancer (BTC).
More positive than 93% of claims this week
Phase II data for ivonescimab in advanced BTC showed an Objective Response Rate of 63.6% and a Disease Control Rate of 100%.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 86% of claims this week
Patient enrollment has been completed for the Phase III registrational study (AK112-309/HARMONi-GI1) evaluating ivonescimab plus chemotherapy.
More positive than 64% of claims this week
This is the fifth Breakthrough Therapy Designation awarded to ivonescimab, following prior designations in lung cancer and triple-negative breast cancer.
So whatRepeated designations suggest a versatile platform with broad therapeutic potential, improving the long-term valuation of the asset.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received its fifth Breakthrough Therapy Designation from the NMPA for ivonescimab, indicating strong clinical potential and accelerated regulatory review.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
10h ago
—
No price for 9926.HK right now — the quote feed didn't answer.
9926.HK chart →
